Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Uwe Christians to Tacrolimus

This is a "connection" page, showing publications Uwe Christians has written about Tacrolimus.

 
Connection Strength
  
 
 
4.412
  
  1. Alloway RR, Vinks AA, Fukuda T, Mizuno T, King EC, Zou Y, Jiang W, Woodle ES, Tremblay S, Klawitter J, Klawitter J, Christians U. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. PLoS Med. 2017 Nov; 14(11):e1002428.
    View in: PubMed
    Score: 0.488
  2. Shokati T, Bodenberger N, Gadpaille H, Schniedewind B, Vinks AA, Jiang W, Alloway RR, Christians U. Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS. J Vis Exp. 2015 Nov 08; (105):e52424.
    View in: PubMed
    Score: 0.425
  3. Klawitter J, Klawitter J, Schmitz V, Shokati T, Epshtein E, Thurman JM, Christians U. Mycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolism. PLoS One. 2014; 9(1):e86202.
    View in: PubMed
    Score: 0.375
  4. Klawitter J, Kirkpatrick BE, Shillingburg R, Klawitter J, Wheeler G, Shokati T, Cadnapaphornchai MA, Galinkin JL, Thurman JM, Christians U. Monitoring of Allograft Adaptation After Kidney Transplantation in Pediatric Patients by Targeted Plasma Metabolomics. Int J Mol Sci. 2025 Sep 20; 26(18).
    View in: PubMed
    Score: 0.210
  5. Filler G, Womiloju T, Feber J, Lepage N, Christians U. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant. 2005 Aug; 5(8):2005-10.
    View in: PubMed
    Score: 0.208
  6. Trotter JF, Osborne JC, Heller M, Christians U. Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients. Aliment Pharmacol Ther. 2005 Jul 01; 22(1):37-44.
    View in: PubMed
    Score: 0.207
  7. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002; 41(11):813-51.
    View in: PubMed
    Score: 0.163
  8. Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, Christians U. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther. 2001 Jan; 69(1):24-31.
    View in: PubMed
    Score: 0.152
  9. Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit. 2019 06; 41(3):261-307.
    View in: PubMed
    Score: 0.136
  10. Lichvar A, Tremblay S, Naik D, Lipscomb J, King E, Vinks AA, Christians U, Alloway RR. Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients. Pharmacotherapy. 2019 05; 39(5):564-575.
    View in: PubMed
    Score: 0.135
  11. Emoto C, Johnson TN, Hahn D, Christians U, Alloway RR, Vinks AA, Fukuda T. A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition. CPT Pharmacometrics Syst Pharmacol. 2019 05; 8(5):273-284.
    View in: PubMed
    Score: 0.134
  12. Leino AD, King EC, Jiang W, Vinks AA, Klawitter J, Christians U, Woodle ES, Alloway RR, Rohan JM. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am J Transplant. 2019 05; 19(5):1410-1420.
    View in: PubMed
    Score: 0.132
  13. Bittersohl H, Schniedewind B, Christians U, Luppa PB. A simple and highly sensitive on-line column extraction liquid chromatography-tandem mass spectrometry method for the determination of protein-unbound tacrolimus in human plasma samples. J Chromatogr A. 2018 Apr 27; 1547:45-52.
    View in: PubMed
    Score: 0.125
  14. Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A, Sewing KF. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar; 41(3):187-90.
    View in: PubMed
    Score: 0.108
  15. Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf. 1995 May; 12(5):348-57.
    View in: PubMed
    Score: 0.102
  16. Shihab F, Christians U, Smith L, Wellen JR, Kaplan B. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol. 2014 Jun; 31(1):22-32.
    View in: PubMed
    Score: 0.096
  17. Frassetto L, Floren L, Barin B, Browne M, Wolfe A, Roland M, Stock P, Carlson L, Christians U, Benet L. Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos. 2013 Nov; 34(8):442-51.
    View in: PubMed
    Score: 0.091
  18. Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013 Sep; 52(9):751-62.
    View in: PubMed
    Score: 0.091
  19. Chitnis SD, Ogasawara K, Schniedewind B, Gohh RY, Christians U, Akhlaghi F. Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. Xenobiotica. 2013 Jul; 43(7):641-9.
    View in: PubMed
    Score: 0.087
  20. Christians U, Braun F, Schmidt M, Kosian N, Schiebel HM, Ernst L, Winkler M, Kruse C, Linck A, Sewing KF. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. Clin Chem. 1992 Oct; 38(10):2025-32.
    View in: PubMed
    Score: 0.086
  21. Christians U, Braun F, Kosian N, Schmidt M, Schiebel HM, Ernst L, Kruse C, Winkler M, Holze I, Linck A, et al. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. Transplant Proc. 1991 Dec; 23(6):2741-4.
    View in: PubMed
    Score: 0.081
  22. Christians U, Braun F, Sattler M, Almeidal VM, Linck A, Sewing KF. Interactions of FK 506 and cyclosporine metabolism. Transplant Proc. 1991 Dec; 23(6):2794-6.
    View in: PubMed
    Score: 0.081
  23. Christians U, Klawitter J, Clavijo CF. Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int Suppl. 2010 Mar; (115):S1-7.
    View in: PubMed
    Score: 0.072
  24. Filler G, Bendrick-Peart J, Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit. 2008 Apr; 30(2):138-42.
    View in: PubMed
    Score: 0.063
  25. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001 Apr; 23(2):119-28.
    View in: PubMed
    Score: 0.039
  26. Braun F, Christians U, Laabs S, Elias K, Shipkova M, Schütz E, Ringe B. An ex vivo model to study the intestinal biotransformation of immunosuppressive drugs. Transplant Proc. 2000 Nov; 32(7):1999.
    View in: PubMed
    Score: 0.037
  27. Braun F, Christians U, Laabs S, Elias K, Shipkova M, Schütz E, Ringe B. An ex vivo model to study the intestinal biotransformation of immunosuppressives. Transplant Proc. 2000 Nov; 32(7):2536.
    View in: PubMed
    Score: 0.037
  28. Braun F, Schütz E, Christians U, Lorf T, Schiffmann JH, Armstrong VW, Schröter W, Sewing KF, Oellerich M, Ringe B. Pitfalls in monitoring tacrolimus (FK 506). Ther Drug Monit. 1997 Dec; 19(6):628-31.
    View in: PubMed
    Score: 0.031
  29. Winkler M, Christians U, Baumann J, Gonschior AK, Wonigeit K, Pichlmayr R. Evaluation of the Pro-Trac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart, and liver transplantation. Ther Drug Monit. 1996 Dec; 18(6):640-6.
    View in: PubMed
    Score: 0.029
  30. Braun F, Lorf T, Schütz E, Christians U, Grupp C, Sattler B, Canelo R, Sewing KF, Armstrong VW, Oellerich M, Ringe B. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. Transplant Proc. 1996 Dec; 28(6):3175-6.
    View in: PubMed
    Score: 0.029
  31. Gonschior AK, Christians U, Winkler M, Linck A, Baumann J, Sewing KF. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem. 1996 Sep; 42(9):1426-32.
    View in: PubMed
    Score: 0.028
  32. Lampen A, Christians U, Gonschior AK, Bader A, Hackbarth I, von Engelhardt W, Sewing KF. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol. 1996 Apr; 117(8):1730-4.
    View in: PubMed
    Score: 0.027
  33. Bader A, Knop E, Böker KH, Crome O, Frühauf N, Gonschior AK, Christians U, Esselmann H, Pichlmayr R, Sewing KF. Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry. Naunyn Schmiedebergs Arch Pharmacol. 1996 Mar; 353(4):461-73.
    View in: PubMed
    Score: 0.027
  34. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, Christians U, Winkler M, Fitzsimmons WE, Lieberman R, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 1995 Dec; 17(6):606-14.
    View in: PubMed
    Score: 0.027
  35. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, Sewing KF. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos. 1995 Dec; 23(12):1315-24.
    View in: PubMed
    Score: 0.027
  36. Gonschior AK, Christians U, Winkler M, Schiebel HM, Linck A, Sewing KF. Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. Ther Drug Monit. 1995 Oct; 17(5):504-10.
    View in: PubMed
    Score: 0.026
  37. Winkler M, Wonigeit K, Undre N, Ringe B, Oldhafer K, Christians U, Pichlmayr R. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. Transplant Proc. 1995 Feb; 27(1):822-5.
    View in: PubMed
    Score: 0.025
  38. Gonschior AK, Christians U, Braun F, Winkler M, Linck A, Baumann J, Sewing KF. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). Br J Clin Pharmacol. 1994 Dec; 38(6):567-71.
    View in: PubMed
    Score: 0.025
  39. Winkler M, Christians U, Stoll K, Baumann J, Pichlmayr R. Comparison of different assays for the quantitation of FK 506 levels in blood or plasma. Ther Drug Monit. 1994 Jun; 16(3):281-6.
    View in: PubMed
    Score: 0.024
  40. Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, Christians U, Thurman JM. Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol. 2013 Nov; 24(11):1849-62.
    View in: PubMed
    Score: 0.023
  41. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992 Sep-Oct; 20(5):753-61.
    View in: PubMed
    Score: 0.021
  42. Christians U, Radeke HH, Kownatzki R, Schiebel HM, Schottmann R, Sewing KF. Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. Clin Biochem. 1991 Jun; 24(3):271-5.
    View in: PubMed
    Score: 0.020
  43. Sewing KF, Christians U. FK 506. Lancet. 1991 Feb 23; 337(8739):499.
    View in: PubMed
    Score: 0.019
  44. Christians U, Kruse C, Kownatzki R, Schiebel HM, Schwinzer R, Sattler M, Schottmann R, Linck A, Almeida VM, Braun F, et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. Transplant Proc. 1991 Feb; 23(1 Pt 2):940-1.
    View in: PubMed
    Score: 0.019
  45. Wiseman AC, Kam I, Christians U, Jani A, Bak T, Wachs M, Chan L. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience. Transplant Proc. 2003 May; 35(3 Suppl):122S-124S.
    View in: PubMed
    Score: 0.011
  46. van Gelder T, Klupp J, Sawamoto T, Christians U, Morris RE. ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications. Transplant Proc. 2001 May; 33(3):2420-1.
    View in: PubMed
    Score: 0.010
  47. Hoof T, Demmer A, Christians U, Tümmler B. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. Eur J Pharmacol. 1993 Jun 15; 246(1):53-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)